A Review on the Relationship between Aspirin and Bone Health

Journal of Osteoporosis

Volumn 2017, Issue , 2017, Pages

  Chin, Kok Yong ^a  

^a Malaysia Medical Centre   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALKALINE PHOSPHATASE; DIETHYLSTILBESTROL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PROSTAGLANDIN E2; SALCATONIN; TRANSCRIPTION FACTOR RUNX2;

ARTICLE; BONE DENSITY; BONE MARROW DERIVED MESENCHYMAL STEM CELL; BONE REMODELING; BONE STRENGTH; BONE TURNOVER; DRUG MEGADOSE; ESTROGEN DEFICIENCY; HIP FRACTURE; HUMAN; LOW DRUG DOSE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOPOROSIS; OVARIECTOMY-INDUCED OSTEOPOROSIS; PATHOLOGIC FRACTURE; POSTMENOPAUSE OSTEOPOROSIS; SKELETON;

EID: 85010677259     PISSN: 20908059     EISSN: 20420064     Source Type: Journal    
DOI: 10.1155/2017/3710959     Document Type: Article

References (37)

1. L. J. Raggatt andN. C. Partridge, "Cellular, molecularmechanisms of bone remodeling, " Journal of Biological Chemistry, vol. 285, no. 33, pp. 25103-25108, 2010.
2. A. E. Kearns, S. Khosla, P. J. Kostenuik, "Receptor activator of nuclear factor B ligand, osteoprotegerin regulation of bone remodeling in health, disease, " Endocrine Reviews, vol. 29, no. 2, pp. 155-192, 2008.
3. D. J. Hadjidakis, I. I. Androulakis, "Bone remodeling, " Annals of the New York Academy of Sciences, vol. 1092, pp. 385-396, 2006.
4. L. G. Raisz, "Potential impact of selective cyclooxygenase-2 inhibitors on bone metabolism in health, disease, " The American Journal of Medicine, vol. 110, no. 3, supplement 1, pp. 43-45, 2001.
5. D. Agas, L. Marchetti, M. Capitani, M. G. Sabbieti, "The dual face of parathyroid hormone, prostaglandins in the osteoimmune system, " American Journal of Physiology-Endocrinology andMetabolism, vol. 305, no. 10, pp. E1185-E1194, 2013.
6. K. A. Blackwell, L. G. Raisz, C. C. Pilbeam, "Prostaglandins in bone: bad cop, good cop?" Trends in Endocrinology, Metabolism, vol. 21, no. 5, pp. 294-301, 2010.
7. H. Liu, W. Li, Y. Liu, X. Zhang, Y. Zhou, "Co-administration of aspirin, allogeneic adipose-derived stromal cells attenuates bone loss in ovariectomized rats through the antiinflammatory, chemotactic abilities of aspirin, " Stem Cell Research andTherapy, vol. 6, no. 1, article no. 200, 2015.
8. K. Suda, N. Udagawa, N. Sato, et al., "Suppression of osteoprotegerin expression by prostaglandin e2 is crucially involved in lipopolysaccharide-induced osteoclast formation, " Journal of Immunology, vol. 172, no. 4, pp. 2504-2510, 2004.
9. Y. Zhou, D. M. Boudreau, A. N. Freedman, "Trends in the use of aspirin, nonsteroidal anti-inflammatory drugs in the general U. S. population, " Pharmacoepidemiology, Drug Safety, vol. 23, no. 1, pp. 43-50, 2014.
10. B. Cheng, Y. Kato, S. Zhao, et al., "PGE2 is essential for gap junction-mediated Intercellular communication between osteocyte-like MLO-Y4 cells in response to mechanical strain, " Endocrinology, vol. 142, no. 8, pp. 3464-3473, 2001.
11. V. Fuster, J. M. Sweeny, "Aspirin: a historical, contemporary therapeutic overview, " Circulation, vol. 123, no. 7, pp. 768-778, 2011.
12. E. V. Paez Espinosa, J. P. Murad, F. T. Khasawneh, "Aspirin: pharmacology, clinical applications, " Thrombosis, vol. 2012, Article ID 173124, 15 pages, 2012.
13. D. E. Furst, R. W. Ulrich, S. Prakash, "Nonsteroidal antiinflammatory drugs, disease-modifying antirheumatic drugs, nonopioid analgesics, & drugs used in gout, " in Basic, Clinical Pharmacology, B. G. Katzung, S. B. Masters, A. J. Trevor, Eds., chapter 36, McGraw-Hill, New York, NY, USA, 12th edition, 2012.
14. K. Bibbins-Domingo, D. C. Grossman, S. J. Curry, et al., "Aspirin use for the primary prevention of cardiovascular disease, colorectal cancer: U. S. preventive services task force recommendation statement, " Annals of InternalMedicine, vol. 164, no. 12, pp. 836-845, 2016.
15. S. P. Dehmer, M. V. Maciosek, T. J. Flottemesch, A. B. LaFrance, E. P. Whitlock, "Aspirin for the primary prevention of cardiovascular disease, colorectal cancer: a decision analysis for the U. S. preventive services task force, " Annals of Internal Medicine, vol. 164, no. 12, pp. 777-786, 2016.
16. X. Feng, J. M. McDonald, "Disorders of bone remodeling, " Annual Review of Pathology: Mechanisms of Disease, vol. 6, pp. 121-145, 2011.
17. A. Papaioannou, C. C. Kennedy, G. Ioannidis, et al., "Theimpact of incident fractures on health-related quality of life: 5 years of data from the Canadian multicentre osteoporosis study, " Osteoporosis International, vol. 20, no. 5, pp. 703-714, 2009.
18. C. L. Ekegren, E. R. Edwards, R. Page, et al., "Twelve-month mortality, functional outcomes in hip fracture patients under 65 years of age, " Injury, vol. 47, no. 10, pp. 2182-2188, 2016.
19. S. H. Lee, I. J. Chen, Y. H. Li, C. Y. Fan Chiang, C. H. Chang, P. H. Hsieh, "Incidence of second hip fractures, associated mortality in taiwan: a nationwide population-based study of 95, 484 patients during 2006-2010, " Acta Orthopaedica et Traumatologica Turcica, vol. 50, no. 4, pp. 437-442, 2016.
20. Y. P. Zeng, C. Yang, Y. Li, et al., "Aspirin inhibits osteoclastogenesis by suppressing the activation of NF-B andMAPKs in RANKL-induced RAW264. 7 cells, "MolecularMedicine Reports, vol. 14, no. 3, pp. 1957-1962, 2016.
21. T. Lawrence, "The nuclear factor NF-B pathway in inflammation, " Cold Spring Harbor Perspectives in Biology, vol. 1, no. 6, Article ID a001651, 2009.
22. P. P. Tak, G. S. Firestein, "NF-B: a key role in inflammatory diseases, "The Journal of Clinical Investigation, vol. 107, no. 1, pp. 7-11, 2001.
23. T. Yamaza, Y. Miura, Y. Bi, et al., "Pharmacologic stem cell based intervention as a new approach to osteoporosis treatment in rodents, " PLoS ONE, vol. 3, no. 7, article 2615, 2008.
24. D. J. Waters, D. D. Caywood, G. J. Trachte, R. T. Turner, S. F. Hodgson, "Immobilization increases bone prostaglandin E: effect of acetylsalicylic acid on disuse osteoporosis studied in dogs, " Acta Orthopaedica, vol. 62, no. 3, pp. 238-243, 1991.
25. Z. W. Chen, Z. X. Wu, H. X. Sang, et al., "Effect of aspirin administration for the treatment of osteoporosis in ovariectomized rat model, " Zhonghua yi xue za zhi, vol. 91, no. 13, pp. 925-929, 2011.
26. S. E. Lin, J. P. Huang, L. Z. Wu, T. Wu, L. Cui, "Prevention of osteopenia, dyslipidemia in rats after ovariectomy with combined aspirin, low-dose diethylstilbestrol, " Biomedical, Environmental Sciences, vol. 26, no. 4, pp. 249-257, 2013.
27. J. Wei, J. Wang, Y. Gong, R. Zeng, "Effectiveness of combined salmon calcitonin, aspirin therapy for osteoporosis in ovariectomized rats, " Molecular Medicine Reports, vol. 12, no. 2, pp. 1717-1726, 2015.
28. R. T. Turner, A. Maran, S. Lotinun, et al., "Animal models for osteoporosis, " Reviews in Endocrine, Metabolic Disorders, vol. 2, no. 1, pp. 117-127, 2001.
29. S. Reagan-Shaw, M. Nihal, N. Ahmad, "Dose translation from animal to human studies revisited, " FASEB Journal, vol. 22, no. 3, pp. 659-661, 2008.
30. D. C. Bauer, E. S. Orwoll, K. M. Fox, et al., "Aspirin, NSAID use in older women: effect on bone mineral density, fracture risk, " Journal of Bone andMineral Research, vol. 11, no. 1, pp. 29-35, 1996.
31. P. Vestergaard, P. Hermann, J. E. B. Jensen, P. Eiken, L. Mosekilde, "Effects of paracetamol, non-steroidal antiinflammatory drugs, acetylsalicylic acid, opioids on bone mineral density, risk of fracture: results of the danish osteoporosis prevention study (dops), " Osteoporosis International, vol. 23, no. 4, pp. 1255-1265, 2012.
32. L. D. Carbone, F. A. Tylavsky, J. A. Cauley, et al., "Association between bone mineral density, the use of nonsteroidal anti-inflammatory drugs, aspirin: impact of cyclooxygenase selectivity, " Journal of Bone andMineral Research, vol. 18, no. 10, pp. 1795-1802, 2003.
33. P. Vestergaard, T. H. Steinberg, P. Schwarz, N. R. Jørgensen, "Use of the oral platelet inhibitors dipyridamole, acetylsalicylic acid is associated with increased risk of fracture, " International Journal of Cardiology, vol. 160, no. 1, pp. 36-40, 2012.
34. I. Konstantinidis, S. N. Papageorgiou, A. Kyrgidis, T. G. Tzellos, D. Kouvelas, "Effect of non-steroidal anti-inflammatory drugs on bone turnover: an evidence-based review, " Reviews on Recent Clinical Trials, vol. 8, no. 1, pp. 48-60, 2013.
35. C. Liu, X. Zhang, M. Wu, L. You, "Mechanical loading upregulates early remodeling signals from osteocytes subjected to physical damage, " Journal of Biomechanics, vol. 48, no. 16, pp. 4221-4228, 2015.
36. B. L. Riggs, S. Khosla, L. J. Melton III, "Sex steroids, the construction, conservation of the adult skeleton, " Endocrine Reviews, vol. 23, no. 3, pp. 279-302, 2002.
37. D. Aslan, M. D. Andersen, L. B. Gede, et al., "Mechanisms for the bone anabolic effect of parathyroid hormone treatment in humans, " Scandinavian Journal of Clinical, Laboratory Investigation, vol. 72, no. 1, pp. 14-22, 2012.